PRESENTATION FOR IMMEDIATE RELEASE

For personal use only
PRESENTATION
FOR IMMEDIATE RELEASE
18 MARCH 2010
Pharmaceutical and Healthcare group, Stirling Products Limited
(ASX:STI) is pleased to advise that following the settlement of its
4310 Sq Metre high-tech pharmaceutical production facility in Cape
Breton, Canada and its highly successful launch of ‘Stirling Health’
at the Australian Pharmacy Professional Conference and Trade
Exhibition (APP2010) last weekend, the Company will today
commence a broker roadshow.
The Presentation forms part of this Company Announcement and
follows.
In conjunction with the release of this Presentation the Company
also advises of its new websites launched today which now better
present the Company following the completion of the Company’s
strategic acquisitions and product positioning.
The Company’s major commercialisation drive is now conducted
through five distinct business units. Sales and Manufacturing
Divisions are a prime focus as will be the ongoing commercialisation
works directed towards realising the three distinct blockbuster
product opportunities that the Company has secured.
For further information see www.stirlingproducts.net –
www.stirlinghealth.com.au or contact:
Peter Boonen
Managing Director
Stirling Products Limited
Ph: +61 2 9299 9270
E: peter.boonen@stirlingproducts.net
For all Investor Relations inquiries please contact:
James Moses
Mandate Corporate
Ph: +61 420 991 574
E: james@mandatecorporate.com.au
For personal use only
For personal use only
Broker & Investment
Presentation
March 2010
For personal use only
Forward Moving Statements
This p
presentation p
provides only
y an overview of Stirling
g Products Limited ABN 32 077 105 429
(ASX:STI) and its opportunities. The information may require further explanation and/or
clarification. Accordingly, this information should not be relied upon independently and
should be considered in conjunction with past and future public information and
announcements that are made by STI. Please contact STI and/or refer to the Company's
website for further information.
The views expressed in this presentation may contain information derived from publicly
available sources that have not been independently verified. No representation or warranty
is made as to the accuracy, completeness or reliability of the information. Any forward
looking statements in this presentation have been prepared on a number of assumptions
which may prove incorrect and the current intentions, plans, expectations and beliefs about
future events are subject to risks, uncertainties and other factors, many of which are outside
Stirling Products Limited’s control. These factors could cause actual results to differ
materially from assumptions or expectations expressed or implied in this
presentation. Because actual results may differ materially to assumptions made and STI’s
current intentions, plans, expectations and beliefs about the future, you are urged to view all
forward looking statements contained in this presentation with caution.
caution
Nothing in this presentation should be construed as either an offer to sell or a solicitation of
an offer to buy or sell shares in any jurisdiction.
For personal use only
About Stirling
g Products Limited
ASX:STI
In only 12 months - we have built a global pharmaceutical and healthcare company
Stirling
g now:
• has sales commencing across four divisions
• owns a freehold high-tech $20M+ manufacturing plant in Canada
• owns its future freehold 450 sq m Sydney office HQ
• has a board with global senior industry experience and expertise
• has
h a tteam off world-class
ld l
managers & scientists
i ti t
• owns extensive IP and product range
• owns JV interest in major drug delivery platform
• has three serious blockbuster realization opportunities
For personal use only
2010-2011 Full Year
Positioned for Sales
•
‘Stirling Pharma’ manufacturing base in Canada will concentrate initially on
contract manufacturing - commencing Q2
•
‘Stirling Health’ Australian pharmacy brand launched in March 2010
•
‘Natures Firewall’ to be launched in Q2, 2010 as an Internet based brand
•
‘i N t
‘i-Naturals’
l ’ to
t be
b llaunched
h d iin Q4
Q4, 2010 as a N
Network
t
kM
Marketing
k ti b
brand
d
•
positioned to achieve substantial and sustainable revenues
Positioned for Blockbuster Realization
For personal use only
Corporate
p
– Our Board
•
Directors
Peter Boonen
Managing Director
Neil Covey
Director
G lshan JJugroo
Gulshan
groo
CFO/Director
Professor Glyn Tonge
Non Executive Director
•
The Company’s corporate headquarters are in Sydney, Australia
•
North American operations are based in Prince Edward Island, Canada
•
Manufacturing operations are based at Cape Breton, Canada
•
South African joint venture (Stanimate) based in Johannesburg
For personal use only
Scientific & Management Expertise
Neil Covey – Extensive industry expertise. Former sales and marketing
manager for Bayer Australia
Prof Glyn Tonge – Extensive industry experience. Pharma, corporate finance,
funds manager, funder, M&A, corporate and governance
Michael Elliott – Extensive
E tensi e National Sales Management e
experience
perience with
ith Pfi
Pfizer
er
and Innovex
Dr Allen Bain – pharmacologist who co-developed a block buster antiarrhythmia drug now being commercialized by Merck
Dr Aldar Bourinbaiar – specialist in viral disease, discovered an AIDS treatment
used globally
Dr Galyna Kutsyna – a researcher and specialist in AIDS and viral disease
Dr Manuel Carpio – CEO Canada, Doctor of Veterinary Medicine
Dr Hinner Koster – specialist in animal nutrition and health
Dr Hugo Hattingh – specialist in animal nutrition and health
For personal use only
New Manufacturing
g Facility
y
Stirling’s
Stirling
s 4,310sqm $20M+
$20M Pharmaceutical Plant
For personal use only
New Manufacturing
g Facility
y
Stirling’s
Stirling
s 4,310sqm $20M+
$20M Pharmaceutical Plant
laboratory
For personal use only
New Manufacturing
g Facility
y
Within the current fit-out and configuration the plant has an annual
capacity to manufacture and package over 550 million tablets, 5 million
bottles and blend up to 1.5
1 5 million kg of product
product. It also has a
granulating and grinding capacity.
For personal use only
First Products to Market
Stirling products being launched in markets include:
Stirling Health – Pharmacy Sales
A growing range of OTC, generic, health and beauty products, including
products marketed for third parties
Natural Health Products – Botanicals – ‘Nature’s Firewall’ & ‘i-Naturals’
a range of 26 unique products including:
• ImmunoXel – for immune system optimization
• Cholonorm – for cholesterol health
• Diabetin – contains botanical extracts known to lower blood sugars
• Allergon – for allergies
Immunomodulator and/or adjuvant treatment
• ImmunoXel – for all strains of TB, TB/HIV co-infection, AIDS and influenza
For personal use only
Products in Development
p
Stirling has three fully developed products having blockbuster – company making
potential and which are the subject of ongoing commercialization works:
•
ImmunoXel – as an immunomodulator for treatment of AIDS, TB and flu
•
Inhalation Drug Delivery Platform – proven and patented platform
technology that has demonstrated capability of improved delivery of many
drugs through natural inhalation – this platform provides Stirling the potential
and
d opportunity
t it off securing
i marketshare
k t h
in
i a range off blockbuster
bl kb t d
drugs as
they come off patent
•
R-Salbutamol – world’s only single enantiomer beta agonist patented for
human obesity – trial in beagle dogs demonstrated an approximate 2% per
week weight loss
For personal use only
Drug
g Delivery
y Platform
Key Features
•
Drug transport velocity - matched to the patient’s natural breathing
•
Reduced aerosol losses – less deposition on drug delivery pathways
•
Up to 3 times the aerosol concentration of other ultrasonic devices
•
Provides a concentration level between that currently achieved with dry
powder inhalers and conventional fan driven nebulisers
p
•
Delivered drugs – sub 5 micron - have much better & faster absorption
•
Active drug is in unique disposable capsules – competition protection
•
Testing has shown substantively LESS active drug (than oral) is needed to
provide the same benefit – potential for increased safety and less side
effects
•
Can potentially be used for administration of many major drugs
For personal use only
Products for Human Health
Our p
products and p
pipeline
p
p
products p
provide for agents
g
that are effective in and/or
beneficial for conditions including:
• TB
• AIDS
• Obesity
• Cholesterol
• Diabetes
• Allergies
• Influenza
• Generic Drug delivery
Immunomodulators, such as ImmunoXel, can overcome
bacterial drug resistance since they act through a totally
new immune mechanism.
Our botanical products are the first and only known
products that can enhance the host’s defense against
mycobacterial infections.
Clinical trials have shown some of our products drastically
shortened treatment duration and as an adjuvant contribute
to curing certain conditions
For personal use only
Botanical Products
Why a Focus on Botanicals?
•
The market for herbal and botanical products is forecast to grow by over
168% over the next 5 years to over US$33 billion
•
Over 60% of all New Chemical Entities for prescription pharmaceuticals
in the last 5 years have been derived from natural or synthesized natural
sources
•
There is a race on for the development of all natural immunomodulators
For personal use only
ImmunoXel
Immunomodulator
ImmunoXel has demonstrated in all its clinical trials that it:
•
•
•
•
•
•
•
•
iis a powerful
f l iimmunomodulator
d l t and
d adjuvant
dj
t
substantively tunes the Immune System
enhances efficacy of - antibiotics, viral therapies and chemotherapies
can substantiallyy shorten drug
g and chemotherapy
py treatment duration
can reduce and reverse treatment toxicity side-effects – esp. in liver and
kidneys
is market ready for treatment of TB, TB/HIV, AIDS
over 800 patients treated in clinical trials
– mainly TB, TB/HIV but also AIDS and influenza
is a blockbuster product candidate
For personal use only
Proven in Tuberculosis
ImmunoXel
• Enhances efficacy of drugs 2-10 fold
• Shortens therapy duration 3-12 fold
• Reduces
R d
and
d reverses ttoxicity
i it off
current TB drugs
• Is market ready for TB and TB/HIV
treatment
• Over 800 patients treated in clinical
trials to date
“…a drug effective against drug
resistant TB can earn US$300 million
a year…”
y
- Global TB Alliance
For personal use only
Proven in AIDS Trials
ImmunoXel
In clinical trials when ImmunoXel was used as an adjuvant to anti-retroviral (ART)
chemotherapy in the treatment of AIDS patients and compared to patients only on
ART - ImmunoXel:
I
X l
•
•
•
•
•
•
•
•
•
Significantly increased CD3 T-lymphocytes
CD 4 T cellll population
CD-4
l ti almost
l
td
doubled
bl d
The CD-4/CD-8 ratio increased 29.7%
CD-20 and B-lymphocytes declined to normal levels of around 333
CD-3, HLA-DR and T-cell p
population
p
increased 216%
The CD3, CD16, CD56 and natural killer cells increased by 52.7%
95% of all patients had decrease in viral load burden
Reduced and reversed toxicity side effects of ART
Is market ready for use as an AIDS ART adjuvant treatment
Over 35 million people are living with HIV/AIDS today
For personal use only
Botanical Products
BOTANICAL PRODUCTS AS
DIETARY SUPPLEMENTS
Stirling has joint ventured the
exclusive global marketing rights
to a range of 26 botanical
products that until now have
only been sold through health
care professionals in limited
parts of Europe
Each product has potential
health benefits and has been
tested and proven through
extensive clinical trials in major
academic and research
institutions and also proven
through their extensive use in
Eastern Europe
Condition
Allergies
Anemia
Arthritis
Sore muscles
Asthma
Cholesterol
Heart health
Hypertension
Diabetes and obesity
Immune system
Immune system – preventative
Hormonal imbalance in women
Allergy and autoimmune diseases
Muscle support
Kidney diseases
Neurological diseases
Gastritis, stomach ulcer
Ch i pancreatitis
Chronic
titi & iindigestion
di
ti
Chronic prostatitis
Varicose veins
Indigestion
Rheumatism, arthritis
Thyroid gland dysfunction
Hepatitis
Endocrine disorders
Psycho-emotional stress
Product
ALLERGIL
ANEMIN
ARTROSAN
ARTROSAN-SPORT
BRONCHIN
CHOLENORM
CORDEVIT
CRYSTAL
DIABETIN
IMMUNOXEL
IMMUNOXEL-P
FЕМINAL
LIZORM
MYOTROP
NEPHROPATHIN
NEURIN
NORK
PANCREN
PREDZAREN
PROVEN
RENORM
RHEUMOSAN
SCHIZAREN
SVITANOK
TROPONORM
ZSP
For personal use only
Development
p
ST-810
ST
810 for Obestity
ST- 810 is fully developed, chirally (molecular) pure, and has been safely used by
humans for respiratory disease (asthma) for over 15 years in its purified form and
30 years in its original formulation
formulation.
Stirling is re-purposing this “old drug” for a “new use” - a well established product
development process within the pharmaceutical industry.
ST- 810 is a “metabolic switch” that turns off the body’s fat production receptors
and then lets the body naturally adjust its weight.
To commercialize the ST- 810 product, the Company intends to partner with a
major pharmaceutical group
For personal use only
Major
j Opportunity
pp
y
Obesity
In Australia - the total cost of obesity in 2008 was $58.2 billion which
included the attributable cost of diseases such as diabetes,
cardiovascular disease, various types of cancer and osteoarthritis.
- Weighing it Up: Obesity in Australia May 2009 • House of Representatives Standing
Committee Report on Health and Ageing
In USA - “It's no secret that Americans are fat… Nearly one-third of U.S.
adults are overweight, and another third are technically obese, as
defined by
y a BMI (body-mass
(
y
index)) of more than 30.
30 And Americans
aren't happy about it.
Last year, they spent an estimated $46 Billion on diet products.”
- Forbes
F b Magazine
M
i
For personal use only
Commercialization
Stirling
g Process Strategy
gy
• ‘Stirling Pharma’ starts manufacturing in Q2
• Launch of ‘Stirling Health’ – sales to pharmacies commence April Q2
• Launch
L
h off ‘Nature’s
‘N t
’ Firewall’
Fi
ll’ – Internet
I t
t sales
l network
t
k based
b
d in
i Canada
C
d tto
launch in Q2
• Launch of ‘i-Naturals’ – USA based network marketing health, beauty and
anti aging prod
anti-aging
products
cts to la
launch
nch in Q4 or Q1
Q1, 2011
• Joint venturing of products and/or technologies - ongoing
• Licensing of products, in and out - ongoing
• Relationship establishment with governments and continued clinical trials in
areas of unmet need such as TB and HIV throughout the Africa – ongoing
• Development of pre-production
pre production inhalation platform devices - ongoing
For personal use only
Our Future
Underpinned by Tangible Assets
•
•
$20M+ replacement value - near new, freehold pharmaceutical plant
Freehold offices – est. value $2.5 million
…. positioned for:
• significant sales revenues – commencing early Q2
• realization of major blockbuster potential opportunities
- ImmunoXel as a treatment adjunct for AIDS and TB
- inhalation drug delivery platform
- obesity drug candidate
• jjoint ventures with major
j p
pharmas
• continued aggressive growth
.... to realize:
• market awareness
• re-assessment as an investment opportunity!
For personal use only
Summary
y
Our position is unique. We are positioned as a manufacturer and marketer of
pharmaceutical, generic and healthcare products
In a very short 12 month time-frame we have now launched two of our four sales
initiatives in ‘Stirling Pharma’ and ‘Stirling Health’ and also established our unique
advantage in that most of our products are:
• fully developed
• market ready
Additionally we have serious potential blockbuster opportunity in:
Additionally,
• ImmunoXel with demonstrated unmatched performance in trials for the
treatment of TB and AIDS
• a fully developed Drug Delivery Platform with unprecedented potential
• the IP for a future obesity drug
and:
• our growth
th continues....
ti
For personal use only
Th k you
Thank
Please visit: stirlingproducts.net